Thyrocare Technologies Limited — PPTs, 23-10-2024: Investor Presentation

Thyrocare Technologies reported a robust 20% YoY revenue growth for Q2 FY25, achieving consolidated revenues of ₹177 crore. Key highlights include a 23% increase in normalized EBITDA and a 45% rise in profit after tax. The company acquired the clinical diagnostic business of Vimta Labs, enhancing its footprint in southern India. Operationally, Thyrocare maintains 28 NABL accredited labs, processing 96% of samples at high quality. The strategic focus continues on expanding franchise networks and partnerships.